Javascript must be enabled to continue!
Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development
View through CrossRef
We have generated a series of Erbb2 cDNA knock-in animals to explore the role of signaling pathways coupled to Erbb2 during development. Although this knock-in allele was hypomorphic, expressing tenfold less Erbb2 protein than wild type, the knock-in animals were healthy. However, a further twofold reduction in Erbb2 levels in hemizygous knock-in animals resulted in perinatal lethality with defects in the innervation of the diaphragm. Genetic rescue of this hypomorph was accomplished by expression of the Erbb2-Y1028F mutant in a comparable knock-in allele. Interestingly, hemizygous Y1028F animals were viable with normal innervation of the diaphragm. Molecular analyses revealed that the Y1028F allele expressed higher levels of Erbb2 and that Y1028 promoted the turnover of the receptor. In addition, ablation of the Shc-binding site in Erbb2 (Y1227) resulted in subtle defects in the sensory nerves not observed in the other mutant erbb2 strains. Thus, we have established how Erbb2 levels may be modulated through development and that a minimum threshold level of Erbb2 is required.
The Company of Biologists
Title: Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development
Description:
We have generated a series of Erbb2 cDNA knock-in animals to explore the role of signaling pathways coupled to Erbb2 during development.
Although this knock-in allele was hypomorphic, expressing tenfold less Erbb2 protein than wild type, the knock-in animals were healthy.
However, a further twofold reduction in Erbb2 levels in hemizygous knock-in animals resulted in perinatal lethality with defects in the innervation of the diaphragm.
Genetic rescue of this hypomorph was accomplished by expression of the Erbb2-Y1028F mutant in a comparable knock-in allele.
Interestingly, hemizygous Y1028F animals were viable with normal innervation of the diaphragm.
Molecular analyses revealed that the Y1028F allele expressed higher levels of Erbb2 and that Y1028 promoted the turnover of the receptor.
In addition, ablation of the Shc-binding site in Erbb2 (Y1227) resulted in subtle defects in the sensory nerves not observed in the other mutant erbb2 strains.
Thus, we have established how Erbb2 levels may be modulated through development and that a minimum threshold level of Erbb2 is required.
Related Results
Abstract 1331: The BK5.erbB2 mouse as a novel model of esophageal adenocarcinoma
Abstract 1331: The BK5.erbB2 mouse as a novel model of esophageal adenocarcinoma
Abstract
The incidence of esophageal adenocarcinoma (EAC) is rising rapidly throughout the Western world, and is associated with gastroesophageal reflux disease (GER...
Abstract 1824: Hypoxia induces lapatinib resistance in ErbB2-positive breast cancer cells via regulation of DUSP2
Abstract 1824: Hypoxia induces lapatinib resistance in ErbB2-positive breast cancer cells via regulation of DUSP2
Abstract
Breast cancer is one of the most common cancers among women. Many factors are associated with this disease including overexpression/amplification of the tyr...
Proto-oncogene c-erbB2 initiates rat primordial follicle growth via PKC and MAPK pathways
Proto-oncogene c-erbB2 initiates rat primordial follicle growth via PKC and MAPK pathways
Abstract
Background
c-erbB2, a proto-oncogene coding epidermal growth factor receptor-like receptor, also as a chemosensitivity/prognosis marker ...
Abstract 1823: Novel regulation of Jagged1 by ErbB2 in breast cancer: implications for anti-ErbB2 therapy
Abstract 1823: Novel regulation of Jagged1 by ErbB2 in breast cancer: implications for anti-ErbB2 therapy
Abstract
We have demonstrated that Notch1 is required for trastuzumab resistance in ErbB2 positive breast cancer. This indicates that ErbB2 suppresses Notch1 in brea...
Homologous recombination mRNAs (RAD21, RAD50 and BARD1) have a potentially poor prognostic role in ERBB2-low bladder cancer patients
Homologous recombination mRNAs (RAD21, RAD50 and BARD1) have a potentially poor prognostic role in ERBB2-low bladder cancer patients
AbstractHuman epidermal growth factor receptor 2 (HER2/ERBB2) factor is known to be implicated in many malignancies and the potential of it as a prognostic biomarker was reported y...
ERBB2 activation leads to an anti-oncogenic signalling
ERBB2 activation leads to an anti-oncogenic signalling
Approximately 20% of breast cancers display ERBB2 (HER2) gene amplification and/or protein overexpression. In cancer cells, ERBB2 can function both in the homodimeric and het- erod...
Abstract P3-14-14: Activation of SRC and MAPK Mediates Resistance to Lapatinib in ER-/ERBB2+ Breast Cancer
Abstract P3-14-14: Activation of SRC and MAPK Mediates Resistance to Lapatinib in ER-/ERBB2+ Breast Cancer
Abstract
Background
Resistance to lapatinib represents a significant problem in the treatment of ERBB2+ breast cancer, especially after failure of pri...
Treatment of ErbB2 breast cancer by mitochondrial targeting
Treatment of ErbB2 breast cancer by mitochondrial targeting
Abstract
Background
ErbB2 breast cancer still remains an unmet need due to primary and/or acquired resistance to current treatment strategies. MEDICA compounds consist of synthetic...

